Sponsors / MESO
MESO

Mesoblast, Inc.

Company identity has not yet been verified

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
8Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD ParticipantsNCT00284986Mesoblast, Inc.Phase 2Completed2006-04-25Actual
Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's DiseaseNCT00482092Mesoblast, Inc.Phase 3Completed2014-09-15Actual
Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's DiseaseNCT00543374Mesoblast, Inc.Phase 3Completed2009-07Actual
PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT00683722Mesoblast, Inc.Phase 2Completed2009-03-09Actual
PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)NCT00690066Mesoblast, Inc.Phase 2Completed2010-12-12Actual
Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)NCT00877903Mesoblast, Inc.Phase 2Completed2011-05-18Actual
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's DiseaseNCT01233960Mesoblast, Inc.Phase 3Completed2014-09-15Actual
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart FailureNCT02032004Mesoblast, Inc.Phase 3Completed2020-01-30Actual

Latest recorded trial changes

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure

NCT02032004 · Mesoblast, Inc.

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Time to recurrent non-fatal decompensated heart failure major adverse cardiac events (HF-MACE) that occur prior to the first terminal cardiac event (TCE).

+ Updated value

measure: Time to Recurrent Non-fatal Decompensated Heart Failure Major Adverse Cardiac Events (HF-MACE) That Occur Prior to the First Terminal Cardiac Event (TCE)

Check registry source · The saved outcome text may be shortened. Check the source for full wording.